3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia
1
Kidney Neoplasms
1
Carcinoma, Renal Cell
1
Breast Carcinoma In Situ
1
Brain Neoplasms
1
Advanced Cancer
1
Interventions
Cyclophosphamide
21
fludarabine phosphate
18
Whole-Body Irradiation
17
Methotrexate
17
Tacrolimus
15
Peripheral Blood Stem Cell Transplantation
15
Mycophenolic Acid
13
Dexamethasone
11
Vincristine
10
Etoposide
10
Antilymphocyte Serum
10
Calcium Dobesilate
9
Busulfan
9
Rituximab
8
Doxorubicin
8
merphos
7
Filgrastim
7
Cytarabine
7
Sirolimus
6
Prednisone
6
Melphalan
6
Granulocyte Colony-Stimulating Factor
6
Cyclosporine
6
pegaspargase
5
dexamethasone acetate
5
dexamethasone 21-phosphate
5
prednylidene
4
deltacortene
4
auricularum
4
Radiotherapy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
×
Ranitidine
×
Clear all
NCT02999633
2022-03-21
ISLAY
Sanofi
Phase 2
Terminated
14 enrolled
7 charts